By: IPP Bureau
Last updated : November 14, 2024 10:45 am
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, announces its financial results for the second quarter ended September 30, 2024.
The company reported strong financial performance, achieving a 31% increase in revenue from operations compared to the same period last year. The company has reported Total Revenue from Operations during July – Sept 2024 Rs. 408 crore as compared to Rs. 387.52 crore in April – June 2024. Profit after exceptional item and tax in July – Sept 2024 was Rs. 38.43 crore against the loss Rs. 11.79 crore in April – June 2024.
Commenting on the performance, Bhavana Agrawal, Chief Financial Officer AstraZeneca Pharma India Ltd, said, “We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31% bringing our H1 revenue from operations to Rs. 795.52 crore, driven by our portfolio -Oncology, Biopharmaceuticals and Rare Disease. The growth of the company is a derivative of our ambition to bring innovative medicines faster in the country for unmet patient needs”.
Dr. Sanjeev Panchal, Country President & Managing Director, AstraZeneca Pharma India, said “We are transforming the future of healthcare by unlocking the power of what science can do, for people, society, and planet. With a Growth Through Innovation strategy, we are constantly working towards expanding access to innovative therapies, progressive access strategies, and making healthcare systems resilient in India”.